Does the media prefer TEVA or GSK?

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than GSK. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 8 mentions for GSK. Teva Pharmaceutical Industries' average media sentiment score of 1.26 beat GSK's score of 0.41 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive GSK 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to SNY or TEVA?

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Sanofi. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 8 mentions for Sanofi. Teva Pharmaceutical Industries' average media sentiment score of 1.26 beat Sanofi's score of 1.20 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARGX or TEVA?

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than argenex. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 8 mentions for argenex. Teva Pharmaceutical Industries' average media sentiment score of 1.26 beat argenex's score of 0.79 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TAK or TEVA?

Teva Pharmaceutical Industries has a consensus target price of $41.78, suggesting a potential upside of 29.59%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Teva Pharmaceutical Industries 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.80

Does the media favor RVMD or TEVA?

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Revolution Medicines. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 8 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.52 beat Teva Pharmaceutical Industries' score of 1.26 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Teva Pharmaceutical Industries 13 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Teva Pharmaceutical Industries (TEVA) Competitors

$32.24 +0.68 (+2.15%)

Closing price 03:59 PM Eastern

Extended Trading

$32.27 +0.04 (+0.11%)

As of 04:36 PM Eastern

Compare

TEVA vs. GSK, SNY, ARGX, TAK, and RVMD

Should you buy Teva Pharmaceutical Industries stock or one of its competitors? MarketBeat compares Teva Pharmaceutical Industries with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Teva Pharmaceutical Industries include GSK (GSK), Sanofi (SNY), argenex (ARGX), Takeda Pharmaceutical (TAK), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does Teva Pharmaceutical Industries compare to GSK?

Teva Pharmaceutical Industries (NYSE:TEVA) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Teva Pharmaceutical Industries presently has a consensus price target of $41.78, suggesting a potential upside of 29.59%. GSK has a consensus price target of $53.00, suggesting a potential upside of 0.44%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, research analysts plainly believe Teva Pharmaceutical Industries is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
GSK	2 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.10

GSK has a net margin of 17.82% compared to Teva Pharmaceutical Industries' net margin of 9.01%. GSK's return on equity of 44.28% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
GSK	17.82%	44.28%	11.49%

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

GSK has higher revenue and earnings than Teva Pharmaceutical Industries. GSK is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.15	$1.41B	$1.33	24.24
GSK	$43.07B	2.48	$7.54B	$3.85	13.71

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than GSK. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 8 mentions for GSK. Teva Pharmaceutical Industries' average media sentiment score of 1.26 beat GSK's score of 0.41 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market. Comparatively, GSK has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries and GSK tied by winning 8 of the 16 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Sanofi?

Sanofi (NASDAQ:SNY) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Sanofi currently has a consensus price target of $49.50, indicating a potential upside of 11.97%. Teva Pharmaceutical Industries has a consensus price target of $41.78, indicating a potential upside of 29.59%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Sanofi has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Sanofi. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 8 mentions for Sanofi. Teva Pharmaceutical Industries' average media sentiment score of 1.26 beat Sanofi's score of 1.20 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 1.0% of Sanofi shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Sanofi has a net margin of 16.95% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Sanofi has higher revenue and earnings than Teva Pharmaceutical Industries. Sanofi is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$47.35B	2.26	$8.84B	$3.58	12.35
Teva Pharmaceutical Industries	$17.26B	2.15	$1.41B	$1.33	24.24

Summary

Teva Pharmaceutical Industries beats Sanofi on 10 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to argenex?

argenex (NASDAQ:ARGX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than argenex. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 8 mentions for argenex. Teva Pharmaceutical Industries' average media sentiment score of 1.26 beat argenex's score of 0.79 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has higher revenue and earnings than argenex. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	12.56	$1.29B	$22.46	38.20
Teva Pharmaceutical Industries	$17.26B	2.15	$1.41B	$1.33	24.24

60.3% of argenex shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

argenex has a net margin of 31.31% compared to Teva Pharmaceutical Industries' net margin of 9.01%. argenex's return on equity of 44.37% beat Teva Pharmaceutical Industries' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	44.37%	37.55%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

argenex has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

argenex presently has a consensus target price of $1,037.61, indicating a potential upside of 20.94%. Teva Pharmaceutical Industries has a consensus target price of $41.78, indicating a potential upside of 29.59%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

argenex beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Teva Pharmaceutical Industries has lower revenue, but higher earnings than Takeda Pharmaceutical. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.51T	0.01	-$1.01B	$0.39	42.91
Teva Pharmaceutical Industries	$17.26B	2.15	$1.41B	$1.33	24.24

Takeda Pharmaceutical has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

Teva Pharmaceutical Industries has a consensus target price of $41.78, suggesting a potential upside of 29.59%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Takeda Pharmaceutical's net margin of 4.31%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.20%	5.48%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

In the previous week, Teva Pharmaceutical Industries had 13 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 3 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 1.26 beat Takeda Pharmaceutical's score of 0.97 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 14 of the 16 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Revolution Medicines' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Teva Pharmaceutical Industries has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A
Teva Pharmaceutical Industries	$17.26B	2.15	$1.41B	$1.33	24.24

Revolution Medicines has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Revolution Medicines. MarketBeat recorded 16 mentions for Teva Pharmaceutical Industries and 8 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.52 beat Teva Pharmaceutical Industries' score of 1.26 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Teva Pharmaceutical Industries	13 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines currently has a consensus price target of $144.00, suggesting a potential downside of 19.63%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 29.59%. Given Teva Pharmaceutical Industries' higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Teva Pharmaceutical Industries beats Revolution Medicines on 9 of the 16 factors compared between the two stocks.

Get Teva Pharmaceutical Industries News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TEVA vs. The Competition

Export

Metric	Teva Pharmaceutical Industries	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$37.07B	$5.92B	$6.86B	$23.46B
Dividend Yield	N/A	0.68%	2.68%	4.02%
P/E Ratio	24.24	8.31	27.16	31.12
Price / Sales	2.15	27.78	510.61	163.34
Price / Cash	8.53	8.22	48.63	32.25
Price / Book	4.69	4.36	10.78	4.78
Net Income	$1.41B	$99.67M	$3.59B	$1.07B
7 Day Performance	-2.56%	-2.40%	-2.58%	0.83%
1 Month Performance	-1.95%	9.61%	2.76%	0.92%
1 Year Performance	101.30%	125.27%	25.34%	18.16%

Teva Pharmaceutical Industries Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TEVA Teva Pharmaceutical Industries	4.8155 of 5 stars	$32.24 +2.1%	$41.78 +29.6%	+96.8%	$37.07B	$17.26B	24.24	33,950	Positive News
GSK GSK	2.8342 of 5 stars	$52.30 -0.9%	$53.00 +1.3%	+36.0%	$106.76B	$43.07B	13.59	66,841	Dividend Cut
SNY Sanofi	3.8859 of 5 stars	$44.00 +1.1%	$49.50 +12.5%	-9.2%	$105.46B	$49.35B	12.29	74,846
ARGX argenex	4.5917 of 5 stars	$876.25 -0.2%	$1,037.61 +18.4%	+55.2%	$54.58B	$4.25B	39.01	1,863	News Coverage Upcoming Earnings
TAK Takeda Pharmaceutical	1.8311 of 5 stars	$16.49 -0.4%	N/A	+11.6%	$52.70B	$28.32B	42.28	47,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TEVA) was last updated on 7/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Teva Pharmaceutical Industries (TEVA) Competitors

TEVA vs. GSK, SNY, ARGX, TAK, and RVMD

How does Teva Pharmaceutical Industries compare to GSK?

Summary

How does Teva Pharmaceutical Industries compare to Sanofi?

Summary

How does Teva Pharmaceutical Industries compare to argenex?

Summary

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Summary

How does Teva Pharmaceutical Industries compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA vs. The Competition

Teva Pharmaceutical Industries Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Teva Pharmaceutical Industries (TEVA) Competitors

TEVA vs. GSK, SNY, ARGX, TAK, and RVMD

How does Teva Pharmaceutical Industries compare to GSK?

Do analysts rate TEVA or GSK?

Is TEVA or GSK more profitable?

Do institutionals and insiders hold more shares of TEVA or GSK?

Which has higher valuation & earnings, TEVA or GSK?

Does the media prefer TEVA or GSK?

Which has more risk & volatility, TEVA or GSK?

Summary

How does Teva Pharmaceutical Industries compare to Sanofi?

Do analysts rate SNY or TEVA?

Which has more volatility & risk, SNY or TEVA?

Does the media refer more to SNY or TEVA?

Do institutionals & insiders have more ownership in SNY or TEVA?

Is SNY or TEVA more profitable?

Which has higher earnings and valuation, SNY or TEVA?

Summary

How does Teva Pharmaceutical Industries compare to argenex?

Does the media refer more to ARGX or TEVA?

Which has higher valuation & earnings, ARGX or TEVA?

Do institutionals and insiders have more ownership in ARGX or TEVA?

Is ARGX or TEVA more profitable?

Which has more volatility & risk, ARGX or TEVA?

Do analysts prefer ARGX or TEVA?

Summary

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Which has stronger earnings & valuation, TAK or TEVA?

Which has more volatility and risk, TAK or TEVA?

Do analysts prefer TAK or TEVA?

Is TAK or TEVA more profitable?

Does the media refer more to TAK or TEVA?

Do institutionals & insiders hold more shares of TAK or TEVA?

Summary

How does Teva Pharmaceutical Industries compare to Revolution Medicines?

Do institutionals and insiders hold more shares of RVMD or TEVA?

Is RVMD or TEVA more profitable?

Which has stronger valuation and earnings, RVMD or TEVA?

Which has more volatility and risk, RVMD or TEVA?

Does the media favor RVMD or TEVA?

Do analysts recommend RVMD or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TEVA vs. The Competition

Teva Pharmaceutical Industries Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools